High Hemoglobin Levels After Chemoradiation Could Improve Rectal Cancer Outcomes

Publication
Article
Oncology NEWS InternationalOncology NEWS International Vol 10 No 7
Volume 10
Issue 7

SAN FRANCISCO-A retrospective study of patients with locally advanced rectal cancer suggests that maintaining high hemoglobin levels after preoperative chemoradiation could improve 5-year survival.

SAN FRANCISCO—A retrospective study of patients with locally advanced rectal cancer suggests that maintaining high hemoglobin levels after preoperative chemoradiation could improve 5-year survival.

Thinh P. Phan, MD, of M. D. Anderson Cancer Center in Houston, Texas, reported that patients with severe anemia after preoperative adjuvant treatment had worse outcomes than patients with mild anemia or normal hemoglobin levels. The 5-year survival rate was 81% for patients with mild anemia or normal hemoglobin levels after chemoradiation, compared to 64% for those with severe anemia. Hemoglobin rates before and during chemoradiation (as opposed to after chemoradiation) did not affect local control, distant control, or survival.

The investigators concluded that patients with mild anemia or normal hemoglobin levels after treatment were more likely to respond to treatment and have their tumors downstaged than those with severe anemia. "Better tumor downstaging correlated with better long-term survival and better local control," said Dr. Phan. "Overall survival for patients with severe anemia was worse." (See Figure 1.)

No Anemia Therapy

Dr. Phan collaborated with radiation oncologist Nora Janjan, MD, and other M. D. Anderson Cancer Center physicians on the review of 304 patients treated with chemoradiation from 1990 to 1998. The cohort comprised 192 males and 112 females; the mean age was 58. The majority (85%) had T3 tumors, and 62% were N1. Sixty percent of tumors were larger than 6 cm.

Four to 6 weeks before surgery, all the patients received 45 Gy of radiation to the pelvis with 18 mV photons using a three-field belly board technique and 300 mg of fluorouracil given as a continuous infusion. Hemoglobin levels were evaluated weekly before, during, and after adjuvant therapy.

The study divided the cohort into three groups, defining severe anemia as hemoglobin less than 11g/dL. It categorized mild anemia as hemoglobin levels of 11 to 11.9 g/dL for females and 11 to 12.9 g/dL for males. Any female with a hemoglobin level of 12 g/dL or higher and any male with 13 g/dL or higher was put in the normal group.

Before treatment, 34 patients had severe anemia, 40 had mild anemia, and 230 were in the normal range. After treatment, 36 patients were classified with severe anemia, 82 with mild anemia, and 186 in the normal range.

None of the patients received any special therapy for anemia, according to Dr. Phan. The investigators are interested in doing a prospective study, he said, to try to improve outcomes by increasing hemoglobin in patients receiving standard therapy for locally advanced rectal cancer.

Recent Videos
Genetic backgrounds and ancestry may hold clues for better understanding pancreatic cancer, which may subsequently mitigate different disparities.
Factors like genetic mutations and smoking may represent red flags in pancreatic cancer detection, said Jose G. Trevino, II, MD, FACS.
Skin toxicities are common with targeted therapies for GI malignancies but can be remedied by preventative measures and a collaboration with dermatology.
212Pb-DOTAMTATE showed “unexpectedly good” outcomes among those with gastroenteropancreatic neuroendocrine tumors, said Mary Maluccio, MD, MPH, FACS.
Mandating additional immunotherapy infusions may help replenish T cells and enhance tumor penetration for solid tumors, including GI malignancies.
Receiving information regarding tumor-associated antigens or mutational statuses from biopsies may help treatment selection in GI malignancies.
Better defining which patients with GI cancers are preferred candidates for adoptive cellular therapies may help optimize outcomes.
Related Content